NCT07390617

A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

Interrogating Enfortumab Vedotin-associated Neuropathy in Patients With Metastatic Urothelial Carcinoma Receiving Enfortumab Vedotin

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)

Conditions

• Neuropathy
• Urothelial Carcinoma
• Metastatic Urothelial Carcinoma

Interventions

Type	Name	Description
OTHER	Non-therapeutic Nerve Conduction Studies	Non-invasive nerve conduction studies (NCS) offer an objective, quantitative approach to assess peripheral nerve function, particularly in sensory fibers, which are most commonly affected in chemotherapy-induced peripheral neuropathy/CIPN
OTHER	Non-therapeutic assessment of patient-reported neuropathy	To evaluate the incidence and severity of chemotherapy-induced peripheral neuropathy (CIPN) in participants receiving enfortumab vedotin, we will collect non-therapeutic, participant-reported outcomes

Timeline

• Start date: 2026-01-20
• Primary completion: 2028-01-20
• Completion: 2028-01-20
• First posted: 2026-02-05
• Last updated: 2026-02-05

Locations

7 sites across 1 country: United States